TrialJournal of the European Academy of Dermatology and Venereology : JEADV2017
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
L Cai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
this paperpooled ittrialcites it